Imuski 10ml Injection contains Ranitidine at a concentration of 25mg/ml, a histamine H2-receptor antagonist used primarily to reduce gastric acid secretion. It is indicated for the treatment and prevention of conditions associated with excessive stomach acid, including peptic ulcer disease, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and erosive esophagitis. Ranitidine acts by competitively inhibiting histamine at H2 receptors of the gastric parietal cells, thereby decreasing both basal and stimulated acid secretion, resulting in increased gastric pH. This injectable formulation is typically administered intramuscularly or intravenously in hospital settings when oral administration is not feasible or rapid onset of action is required. Dosage and duration of therapy should be determined by the healthcare professional based on the severity of the condition and patient response. Common adverse effects may include headache, dizziness, gastrointestinal disturbances, and rarely, hypersensitivity reactions. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary. Imuski 10ml Injection should be used under strict medical supervision, with monitoring for therapeutic efficacy and potential side effects. It is contraindicated in patients with known hypersensitivity to ranitidine or any component of the formulation.